The Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective immediately.
Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry.
“Daniel Kubitza brings the necessary expertise needed to advance Simris and maximize our technology platform’s potential,” said Jonathan Royce, Board Chairperson at Simris Group.
During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.
“We thank Alexis for her dedication and hard work. With the recent positive result from our ongoing preclinical study with Nuvisan, we reached an important milestone and will now embark on an accelerated growth strategy,” Royce concluded.